Evidence map›Paper›PMID 41431241›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Surface Avidity of Anionic Polypeptide Coatings on Layer-by-Layer Nanoparticles Target Cancer-Associated Amino Acid Transporters.

Ivan S Pires, Margaret M Billingsley, Ezra Gordon, Andrew J Pickering, Eva Cai, Gonzalo J Esparza, Mae L Pryor, Alexander D Stoneman, Aidan Kindopp, Darrell J Irvine and 1 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ivan S PiresKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts, 02139, USA.
Margaret M BillingsleyKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts, 02139, USA.
Ezra GordonDepartment of Chemical Engineering, Massachusetts Institute of Technology, 21 Ames Street, Cambridge, Massachusetts, 02139, USA.
Andrew J PickeringKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts, 02139, USA.
Eva CaiKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts, 02139, USA.
Gonzalo J EsparzaDepartment of Chemical Engineering, Massachusetts Institute of Technology, 21 Ames Street, Cambridge, Massachusetts, 02139, USA.
Mae L PryorKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts, 02139, USA.
Alexander D StonemanKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts, 02139, USA.
Aidan KindoppKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts, 02139, USA.
Darrell J IrvineKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts, 02139, USA.
Paula T HammondKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts, 02139, USA.ORCID 0000-0002-9835-192X

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticlesR01CA235375 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond, Darrell J Irvine · 2019 to 2026
$2.3M
Engineering Next-Generation Nanoparticles One Layer at a TimeF99CA274651 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SUSIN PIRES, IVAN · 2022 to 2023
$96k
Cancer Research UKHoward Hughes Medical InstituteNCI NIH HHS F99 CA274651NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA235375NIH HHS F99CA274651NIH HHS P30-CA14051NIH HHS R01CA235375Ragon Institute of MGH, MIT, and HarvardThe Marble Center for Cancer Nanomedicine
6 · The paper itself

Abstract

Tumor-targeted drug delivery enhances therapeutic efficacy while minimizing toxicity. Layer-by-layer nanoparticles (LbL-NPs) coated with anionic polypeptides selectively bind to cancer cells, though the mechanisms have been unclear. Here, we integrated in silico and in vitro approaches-including gene expression analysis, receptor inhibition, and AI-based protein modeling-to show that poly(L-glutamate) (PLE)-coated LbL-NPs bind with high avidity to SLC1A5, a glutamine transporter overexpressed in cancer. We also discovered that PLE clusters SLC1A5 on the cell membrane, promoting prolonged cell surface retention. Poly(L-aspartate) (PLD)-coated NPs similarly bind SLC1A5 but also interact with faster internalizing transporters of anionic amino acids. Correlation analyses across cancer cell lines confirmed a strong link between transporter expression and nanoparticle (NP) association. These findings demonstrate that dense glutamate or aspartate presentation through electrostatically adsorbed polypeptides enables selective targeting of overexpressed transporters, providing a mechanistic framework for receptor-targeted delivery that leverages metabolic characteristics of a range of solid tumor types.

Indexed as

Amino Acid Transport System ASCNanoparticlesNeoplasmsPeptidesAnionsCell Line, TumorHumansLayer-by-Layer NanoparticlesMinor Histocompatibility AntigensSurface PropertiesAmino Acid Transport System ASCAnionsMinor Histocompatibility AntigensPeptidesSLC1A5 protein, humanCancer targetingDrug deliveryLayer‐by‐layerNanoparticlesPolymer coating

Identifiers

PMID41431241
PMCPMC12910144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.